Latest News on ICUI

Financial News Based On Company


Advertisement
Advertisement

ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference

https://www.manilatimes.net/2026/11/19/tmt-newswire/globenewswire/icu-medical-to-participate-at-the-piper-sandler-38th-annual-healthcare-conference/2474158
ICU Medical, Inc. announced its participation in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1-3, 2026, in New York. Company management will engage in a fireside chat on December 3 at 6:30 a.m. PT (9:30 a.m. ET) and hold one-on-one meetings. A live webcast of the fireside chat will be accessible via the company's investor relations website.

ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference

https://finance.yahoo.com/healthcare/articles/icu-medical-participate-piper-sandler-133000421.html
ICU Medical, Inc. (Nasdaq: ICUI) announced its participation in the Piper Sandler 38th Annual Healthcare Conference. Company management will engage in a fireside chat and one-on-one meetings on Thursday, December 3, 2026, with the fireside chat webcast live on the company's website. The conference is scheduled for December 1-3, 2026, in New York.

ICU Medical, Inc. (ICUI) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/ICUI/
This article provides a detailed financial overview of ICU Medical, Inc. (ICUI), including its current stock price, market performance, and company profile. It highlights key financial metrics such as market cap, PE ratio, and earnings, alongside an overview of its product offerings in medical devices for infusion therapy and vascular access. The report also includes analyst insights, performance comparisons against the S&P 500, and recent earnings trends.

A manager reports 5% or less of ICU Medical (ICUI), with sole voting power over 1.08M shares.

https://www.stocktitan.net/sec-filings/ICUI/schedule-13g-a-icu-medical-inc-de-amended-passive-investment-disclosu-326747fb3204.html
Fuller & Thaler Asset Management, Inc. has filed an Amendment No. 4 to a Schedule 13G/A, reporting beneficial ownership of 1,085,944 common shares of ICU Medical Inc. (ICUI), representing 4.34% of the class as of September 30, 2026. The filing indicates that the manager holds 5% or less of the class, with sole voting power over 1,083,841 shares and sole dispositive power over 1,085,944 shares. This amendment updates their passive investment disclosure for the medical instruments and supplies company.

Director proposes selling 1,700 ICU Medical (ICUI) shares acquired by exercising options.

https://www.stocktitan.net/sec-filings/ICUI/144-icu-medical-inc-de-sec-filing-a2485dbe1fd4.html
ICU Medical, Inc. (ICUI) director Elisha Wade Finney has proposed selling 1,700 common shares, valued at $304,300.00, on or around November 13, 2026. These shares were acquired the same day through the exercise of options under a registered plan. Finney also reported a prior sale of 65 common shares on November 12, 2026, generating gross proceeds of $11,635.00.
Advertisement

ICU Medical, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ICUI) 2026-11-09

https://seekingalpha.com/article/4965439-icu-medical-inc-2026-q3-results-earnings-call-presentation
ICU Medical, Inc. has released its Q3 2026 earnings call presentation, detailing its financial results for the quarter. The company reported an EPS of $2.44, beating estimates by $0.29, and revenue of $560.44M, which represents a 4.37% year-over-year increase and surpassed expectations by $6.48M. This presentation provides investors with key insights into the company's performance.

ICU Medical Holds 2026 Outlook as Third-Quarter Revenue Rises

https://www.tokenpost.com/news/business/50920
ICU Medical maintained its 2026 adjusted profit outlook after a strong third quarter saw revenue increase and net income turn positive. The company expects its full-year adjusted results to be at the higher end of its previously issued guidance ranges for adjusted EBITDA and diluted earnings-per-share. This positive performance was driven by results ahead of expectations for Infusion Systems.

ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London

https://finance.yahoo.com/healthcare/articles/icu-medical-present-2026-jefferies-133000119.html
ICU Medical, Inc. (Nasdaq: ICUI) announced that its management will present at the 2026 Jefferies Global Healthcare Conference in London. The presentation is scheduled for Wednesday, November 18, 2026, at 5:00 p.m. BST (12:00 p.m. ET), with one-on-one meetings also taking place on the same day. A live webcast and replay of the presentation will be available on the company's website.

A live webcast will carry ICU Medical’s conference presentation on Nov. 18.

https://www.stocktitan.net/news/ICUI/icu-medical-to-present-at-the-2026-jefferies-global-healthcare-trnhqbvjag1u.html
ICU Medical (ICUI) announced that its management will present at the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. The presentation is scheduled for 5:00 p.m. BST (12:00 p.m. ET), and a live webcast and replay will be available through the Investors section of the company’s website. Management will also engage in one-on-one meetings during the conference.

ICU Medical Q3 Revenue Rises 4% on Infusion Systems Growth

https://www.tradingkey.com/news/presentation/262291143-
ICU Medical (NASDAQ: ICUI) reported a 4% increase in adjusted revenue to $556 million for the third quarter of 2026, driven by strong growth in its Infusion Systems and Consumables segments. Organic revenue grew 5%, excluding currency movements and the deconsolidation of the IV Solutions business. Despite growth in two segments, the Vital Care category continued to decline, and the company did not disclose profitability metrics for the quarter.
Advertisement

ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London

https://www.globenewswire.com/news-release/2026/11/06/3397501/8573/en/icu-medical-to-present-at-the-2026-jefferies-global-healthcare-conference-in-london.html
ICU Medical, Inc. announced that its management will present at the 2026 Jefferies Global Healthcare Conference in London. The presentation will take place on Wednesday, November 18, 2026, at 5:00 p.m. BST and will be webcast live on the company's website. Management will also hold one-on-one meetings during the conference.

ICU Medical Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:f2fc85f54094b:0-icu-medical-q3-earnings-call-highlights/
ICU Medical reported strong third-quarter results, with revenue of $556 million and adjusted earnings per share of $2.44, driven by growth in infusion products and improved margins. The company expects full-year adjusted earnings to be at the higher end of its guidance despite logistical challenges affecting its Vital Care segment. ICU Medical is also focused on debt reduction and anticipates new product filings and approvals in the near future.

ICU Medical Inc (ICUI) Q3 2026 Earnings Call Highlights: Record Sales, 20% EPS Growth and a ...

https://sg.finance.yahoo.com/news/icu-medical-inc-icui-q3-052830618.html
ICU Medical Inc (ICUI) reported strong Q3 2026 results with $556 million in revenue, a 5% organic growth, and a 20% increase in adjusted EPS to $2.44, driven by record sales in Infusion Systems and Consumables. The company achieved an adjusted gross margin of 42% and generated robust free cash flow, reducing net leverage. Despite a decline in the Vital Care segment due to logistics challenges and macroeconomic pressures like tariffs, ICU Medical is on track with its innovation pipeline and remains focused on achieving its 43% gross margin target by the end of 2027.

ICU Medical Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62959435/icu-medical-q3-2026-earnings-call-transcript
ICU Medical Inc. reported strong Q3 2026 results with revenue of $556 million, reflecting 5% organic growth and adjusted EPS of $2.44. The company successfully repaid $80 million in debt, reducing net leverage below 2 times, and reaffirmed its 2026 guidance, expecting to hit the higher end of its EBITDA and EPS range. Strategic initiatives, including distribution network consolidation and new product innovation, are progressing towards a long-term goal of a 43% gross margin by 2027.

ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range

https://www.globenewswire.com/news-release/2026/11/05/3397067/8573/en/icu-medical-announces-third-quarter-2026-results-and-reaffirms-fiscal-year-2026-guidance-expecting-results-at-the-high-end-of-range.html
ICU Medical, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting GAAP revenue of $560.4 million and GAAP net income of $26.8 million, or $1.07 per diluted share. The company reaffirmed its fiscal year 2026 guidance, expecting results to be at the higher end of the previously provided ranges for both GAAP net income and Adjusted EBITDA. Vivek Jain, CEO, noted that Infusion Systems results were ahead of expectations, while other business segments performed in line.
Advertisement

ICU Medical (NASDAQ:ICUI) surprises with Q3 2026 sales

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-5-icu-medical-nasdaqicui-surprises-with-q3-2026-sales
ICU Medical (NASDAQ: ICUI) reported strong Q3 2026 results, surpassing market expectations for both revenue and non-GAAP profit. The medical device company saw its revenue increase by 5.1% year-on-year to $560.4 million, and its adjusted EPS of $2.44 beat analyst estimates by 13.6%. The company's shares remained flat immediately after the announcement, trading at $167.46.

ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range

https://www.globenewswire.com/news-release/2026/11/05/3397067/0/en/icu-medical-announces-third-quarter-2026-results-and-reaffirms-fiscal-year-2026-guidance-expecting-results-at-the-high-end-of-range.html
ICU Medical (Nasdaq: ICUI) announced its third-quarter 2026 financial results, reporting GAAP revenue of $560.4 million and GAAP net income of $26.8 million, or $1.07 per diluted share. The company also reaffirmed its fiscal year 2026 guidance, expecting results at the higher end of the previously stated range for both GAAP net income and Adjusted EBITDA. The solid performance was attributed to strong results in Infusion Systems and alignment with expectations across the rest of the business.

ICU Medical posted a $26.8 million third-quarter profit after a $3.4 million loss a year earlier.

https://www.stocktitan.net/news/ICUI/icu-medical-announces-third-quarter-2026-results-and-reaffirms-4shzswzigoq7.html
ICU Medical (Nasdaq: ICUI) returned to profitability in the third quarter of 2026, reporting GAAP net income of $26.8 million, up from a $3.4 million loss a year earlier. Revenue increased to $560.4 million, and diluted earnings reached $1.07 per share. The company reaffirmed its fiscal year 2026 guidance, expecting results at the higher end of the range.

iRhythm, ICU Medical, Globus Medical, Enovis, and CONMED shares are soaring, what you need to know

https://www.tradingview.com/news/stockstory:c69b597e5094b:0-irhythm-icu-medical-globus-medical-enovis-and-conmed-shares-are-soaring-what-you-need-to-know/
Shares of several medical technology companies, including iRhythm, ICU Medical, Globus Medical, Enovis, and CONMED, surged following election results that confirmed Democrats gained majorities in Congress. This outcome eased regulatory uncertainty regarding drug pricing policy, which Wall Street analysts believe will strengthen the biopharmaceutical sector's recovery. Investors also viewed the shifting balance of power in Washington as a stabilizing dynamic, supporting ongoing investments in the pharmaceutical and biotechnology industries.

ICU Medical (ICUI) Q3 earnings: what to expect

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-icu-medical-icui-q3-earnings-what-to-expect
ICU Medical (NASDAQ: ICUI) is set to report its Q3 earnings this Thursday after market hours. Analysts anticipate a 3.5% year-on-year revenue growth, a reversal from the previous year's decline. The company has a history of exceeding Wall Street's expectations, and its stock price is currently below the average analyst price target.
Advertisement

Understanding the Setup: (ICUI) and Scalable Risk

https://news.stocktradersdaily.com/news_release/101/Understanding_the_Setup:_ICUI_and_Scalable_Risk_110126092602_1793586362.html
This article analyzes Icu Medical Inc. (NASDAQ: ICUI), highlighting a neutral near and mid-term outlook but a positive long-term bias. It identifies an exceptional 41.2:1 risk-reward setup, targeting a 12.0% gain with only 0.3% risk. The analysis includes AI-generated institutional trading strategies for position trading, momentum breakouts, and risk hedging, along with multi-timeframe signal analysis.

Earnings Preview: ICU Medical to Report Financial Results Post-market on November 05

https://www.moomoo.com/news/post/1003075541/earnings-preview-icu-medical-to-report-financial-results-post-market
ICU Medical (ICUI) is scheduled to release its financial results after the market closes on November 5. Analysts anticipate the company will report quarterly earnings of $1.52 per share and revenue of $296.84 million. Investors will be keen to see if the company meets or surpasses these expectations.

ICU Medical Q2 Earnings Call Highlights

https://fr.tradingview.com/news/marketbeat:26fe10e95094b:0-icu-medical-q2-earnings-call-highlights/
ICU Medical reported Q2 revenue of $548 million, a 6% organic increase, driven by strong performance in consumables and infusion systems. The company raised its full-year adjusted EBITDA and EPS guidance, anticipating continued growth despite headwinds in Vital Care and OEM revenue. Management emphasized competitive wins in pump installations and stabilization in Vital Care after product rationalization efforts.

ICU Medical, Inc. (ICUI) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ICUI/seasonality/
This page provides a seasonal returns chart for ICU Medical, Inc. (ICUI), displaying average monthly price returns from 2016 to 2026. The financial data includes the real-time Nasdaq price and after-hours trading information for ICUI. It also offers links to various financial data points such as news, charts, statistics, and historical data for the company.

ICU Medical, Inc. Estimates – NASDAQ:ICUI

https://www.tradingview.com/symbols/NASDAQ-ICUI/financials-estimates/
This page provides financial estimates for ICU Medical, Inc. (NASDAQ:ICUI), including reported financial data and analyst estimates across various financial statements. Users can explore actual results versus average, high, and low estimates, and visualize trends over time for income statements, balance sheets, and cash flow data. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
Advertisement

ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call

https://www.globenewswire.com/news-release/2026/10/22/3386355/8573/en/icu-medical-announces-time-of-third-quarter-2026-earnings-conference-call.html
ICU Medical, Inc. (Nasdaq: ICUI) announced the schedule for its third quarter 2026 earnings release and conference call. The company will release its results on Thursday, November 5, 2026, around 4:00 p.m. ET, with a conference call following at 4:30 p.m. ET. The call details and webcast access were provided for interested parties.

ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call

https://www.globenewswire.com/fr/news-release/2026/10/22/3386355/8573/en/icu-medical-announces-time-of-third-quarter-2026-earnings-conference-call.html
ICU Medical, Inc. (Nasdaq: ICUI) announced the schedule for its third quarter 2026 earnings release and conference call. The company will release its financial results on Thursday, November 5, 2026, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET on the same day. The call details and webcast information are provided for investors and interested parties.

Argus raises target for ICU Medical stock to USD 171.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/argus-raises-target-for-icu-medical-stock-to-usd-171-00/70377869
Argus has raised its price target for ICU Medical (ICUI) stock to USD 171.00, with the company scheduled to report its third-quarter 2026 results on November 5, 2026. ICU Medical, a Nasdaq-listed medical technology company, last traded at USD 160.84, with a market capitalization of USD 4.0 billion and a trailing P/E of 136.28. The company's second-quarter 2026 performance showed USD 551.70 million in revenue and diluted EPS of USD 0.76, exceeding consensus estimates for adjusted EPS.

ICU Medical stock faces an 18.29 percent gap to USD 192.80 target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/icu-medical-stock-faces-an-18-29-percent-gap-to-usd-192-80-target/70350040
ICU Medical (ICUI) stock is currently priced at USD 162.99, presenting an 18.29% gap to the average analyst target of USD 192.80. The company recently raised its fiscal-year 2026 adjusted earnings per share guidance to USD 8.60-9.00. Investors are anticipating the next earnings report on November 5, 2026, to see if the improved outlook can help close this valuation gap.

ICU Medical, Inc. (ICUI) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4068_QuantitativeReport_1791936000000
Argus has raised its target price for ICU Medical, Inc. (ICUI) to $171.00, an increase from its previous target. The company, a California-based pure-play infusion therapy provider, currently trades at $162.99. This revised forecast is based on an analyst report dated October 14, 2026.
Advertisement

ICU Medical is due to report November 5, 2026: what it means for ICU Medical stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/icu-medical-is-due-to-report-november-5-2026-what-it-means-for-icu-medical-stock/70332707
ICU Medical (ICUI) is estimated to report its third-quarter 2026 results on November 5, 2026. The company's stock was trading at EUR 148.50 on October 15, 2026, with a market capitalization of USD 4.2 billion and a P/E ratio of 141.22. Investors anticipate the report for updates on revenue, earnings, and the full-year outlook, with expected third-quarter revenue of USD 552.07 million.

ICU Medical is due to report November 5, 2026: what it means for ICU Medical stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/icu-medical-is-due-to-report-november-5-2026-what-it-means-for-icu/70332707
ICU Medical is expected to report its third-quarter 2026 results on November 5, 2026. The company's second-quarter 2026 revenue was USD 551.70 million, and its stock was trading at EUR 148.50 on October 15, 2026, with a market capitalization of USD 4.2 billion. Investors will be looking to the upcoming report for revenue, earnings, and management's full-year outlook.

Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve Cannabis

https://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-highlights-icu-115500515.html
The Zacks Medical Products industry faces cost and execution pressures but is driven by innovation, resilient healthcare utilization, and strong demand for products addressing chronic conditions. The article highlights ICU Medical (ICUI), Neogen (NEOG), and Trulieve Cannabis Corp. (TRLV) as three companies with distinct growth narratives poised to benefit from these industry trends, despite overall underperformance of the sector compared to the S&P 500. It delves into the specific catalysts and risks for each company, noting their Zacks Ranks and VGM scores.

Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve Cannabis

https://www.theglobeandmail.com/investing/markets/stocks/TRLV/pressreleases/6175075/zacks-industry-outlook-highlights-icu-medical-neogen-and-trulieve-cannabis/
Zacks Equity Research highlights three medical product stocks—ICU Medical, Neogen, and Trulieve Cannabis Corp.—positioned for growth in the latter half of 2026, despite industry-wide cost and execution pressures. The article details major trends shaping the medical products industry, including continuous innovation, migration to ambulatory care, and the increasing adoption of AI and robotics. It also provides an industry performance overview and specific reasons why these three companies are considered strong buys.

ICU Medical, Inc. (ICUI) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4068_QuantitativeReport_1790726400000
Argus has raised its target price for ICU Medical (ICUI) to $172.00. The company is described as a California-based pure-play infusion therapy provider. This report provides an earnings estimate and the current stock price, along with related analyst reports for other healthcare companies.
Advertisement

MarketBeat rates ICU Medical stock Moderate Buy with USD 200 target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/marketbeat-rates-icu-medical-stock-moderate-buy-with-usd-200-target/70250381
MarketBeat has rated ICU Medical (ICUI) stock as a "Moderate Buy" with a target price of USD 200 from Raymond James, contributing to an average analyst target of USD 192.80. Despite a flat revenue of USD 551.70 million in Q2 2026, diluted EPS decreased, and net income fell by 46% year-over-year. The stock traded at USD 159.73 on October 6, 2026, below its 52-week high, with analysts noting margin execution as a key factor against higher targets.

ICU Medical stock faces recall scrutiny after Q2 results

https://www.ad-hoc-news.de/boerse/news/corporate-news/icu-medical-stock-faces-recall-scrutiny-after-q2-results/70231233
ICU Medical (ICUI) stock is under scrutiny due to two Class II recalls affecting CADD reservoirs and Plum administration sets, impacting over 185,000 and 163 million units respectively. This comes as the company reported Q2 2026 revenue of $551.7 million, exceeding consensus estimates of $533.4 million, and updated its fiscal 2026 EPS guidance to $8.60-$9.00. Analysts maintain a "Moderate Buy" rating with an average 12-month price target of $192.80, despite the stock trading below its 52-week high amid concerns over product reliability and recall execution.

(ICUI) Movement Within Algorithmic Entry Frameworks

https://news.stocktradersdaily.com/news_release/91/ICUI_Movement_Within_Algorithmic_Entry_Frameworks_100226054202_1790934122.html
Icu Medical Inc. (NASDAQ: ICUI) is exhibiting mixed sentiment with weak near-term outlook but strong long-term potential, according to algorithmic analysis. The article outlines various trading strategies including long, breakout, and short positions with specific entry, target, and stop-loss levels. It also provides a multi-timeframe signal analysis indicating support and resistance levels.

Analysts Offer Insights on NA Companies: Hexcel (HXL), International Paper Co (IP) and ICU Medical (ICUI)

https://www.theglobeandmail.com/investing/markets/stocks/HXL/pressreleases/4774333/analysts-offer-insights-on-na-companies-hexcel-hxl-international-paper-co-ip-and-icu-medical-icui/
This article highlights bullish sentiments from analysts for three North American companies: Hexcel (HXL), International Paper Co (IP), and ICU Medical (ICUI). RBC Capital maintained a Buy rating on Hexcel with a $115 price target, while J.P. Morgan reiterated a Buy rating on International Paper Co with a $62 price target. Piper Sandler also reiterated a Buy rating on ICU Medical, setting a price target of $195.

Analysts Offer Insights on NA Companies: Hexcel (HXL), International Paper Co (IP) and ICU Medical (ICUI)

https://www.theglobeandmail.com/investing/markets/stocks/ICUI/pressreleases/4774333/analysts-offer-insights-on-na-companies-hexcel-hxl-international-paper-co-ip-and-icu-medical-icui/
This article highlights bullish sentiments from analysts on three North American companies: Hexcel (HXL), International Paper Co (IP), and ICU Medical (ICUI). RBC Capital maintained a Buy rating on Hexcel with a $115 price target, while J.P. Morgan reiterated a Buy on International Paper Co with a $62 price target, and Piper Sandler reaffirmed a Buy rating on ICU Medical with a $195 price target. The analysis includes details on each analyst's performance and the overall consensus rating for each stock.
Advertisement

ICU Medical, Inc. (ICUI) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_4068_QuantitativeReport_1790121600000/
Argus has issued a stock forecast for ICU Medical, Inc. (ICUI), raising its target price to $169.00 from a current price of $166.02. The report, dated September 23, 2026, describes ICU Medical as a California-based pure-play infusion therapy company.

A Look at ICU Medical Inc (ICUI) After 3.7% Gain -- GF Value $121.40 vs Price $160.98

https://www.gurufocus.com/news/9092603/a-look-at-icu-medical-inc-icui-after-37-gain-gf-value-12140-vs-price-16098
ICU Medical Inc (ICUI) shares recently rose 3.7% to $160.98, significantly above its GF Value™ estimate of $121.40, indicating it is "Significantly Overvalued." The company has a strong GF Score™ of 83/100, driven by profitability and momentum, but its valuation rank is weak, and insiders have sold $8.3 million in shares with no buying activity, suggesting caution for investors.

Otsuka ICU Medical Recalls One Lot of IV Saline After Potassium Chloride Bag Found Inside Saline Overwrap

https://www.medicaldaily.com/otsuka-icu-medical-saline-recall-potassium-chloride-lot-1042188-478872
Otsuka ICU Medical LLC has issued a recall for one lot of 0.9% Sodium Chloride Injection, USP (saline) after a customer discovered a bag of concentrated potassium chloride inside a saline-labeled overwrap. The recall, affecting lot 1042188, targets hospitals and clinics, though no adverse events have been reported. The primary safeguard against accidental administration is the clear labeling on the inner potassium chloride bag, requiring healthcare professionals to check before use.

ICU Medical CFO Sells 6,381 Shares for $1.1 Million

https://finance.yahoo.com/markets/stocks/articles/icu-medical-cfo-sells-6-221501622.html
ICU Medical's CFO, Brian Michael Bonnell, sold 6,381 shares of common stock for $1.1 million on September 1, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Bonnell retains 56,062 shares valued at approximately $9.5 million, indicating continued confidence in the company. The sale is considered routine and not a cause for alarm, especially given ICU Medical's recent positive financial performance and stock growth.

Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection

https://www.prnewswire.com/news-releases/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-injection-usp-due-to-a-product-mix-up-with-10-meq-potassium-chloride-injection-302882654.html
Otsuka ICU Medical LLC is initiating a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL due to a potential product mix-up. The recall stems from a customer complaint where a 10 mEq Potassium Chloride Injection 100 mL bag was found inside an overwrap labeled for Sodium Chloride Injection. Inadvertent injection of highly concentrated potassium chloride carries a reasonable probability of adverse events, including neuromuscular dysfunction, cardiac dysrhythmias, and potentially fatal outcomes, especially for vulnerable patient populations.
Advertisement

ICU Medical at Wells Fargo conference: focus shifts to cash returns

https://www.investing.com/news/transcripts/icu-medical-at-wells-fargo-conference-focus-shifts-to-cash-returns-93CH-4896443
At the Wells Fargo 21st Annual Healthcare Conference, ICU Medical (ICUI) outlined a strategy focused on portfolio discipline, operational improvements, and a future shift towards shareholder returns through buybacks and dividends. The company aims to reach a 2x leverage ratio by the end of 2024, after which it plans to prioritize returning capital to shareholders. While IV systems and consumables show mid-single-digit growth, the Vital Care segment continues to be a drag, and management seeks to improve gross margins and cash flow conversion.

ICU Medical at Wells Fargo conference: focus shifts to cash returns

https://ca.investing.com/news/stock-market-news/icu-medical-at-wells-fargo-conference-focus-shifts-to-cash-returns-93CH-4835257
ICU Medical (ICUI) presented at the Wells Fargo 21st Annual Healthcare Conference, outlining a strategic shift towards shareholder returns after years of building an integrated infusion business. The company expects to achieve a 2x leverage ratio by the end of 2024, after which it plans to prioritize buybacks and dividends. While core businesses like IV systems and consumables are performing well, the Vital Care segment remains a drag, and the company is not planning increased investment in it, opting to operate it until better options emerge.

ICU Medical Insider Sold Shares Worth $1,116,675, According to a Recent SEC Filing

https://www.marketscreener.com/news/icu-medical-insider-sold-shares-worth-1-116-675-according-to-a-recent-sec-filing-ce7858d2db8efe22
An insider at ICU Medical, Inc. sold shares worth $1,116,675, as disclosed in a recent SEC filing. This transaction follows other insider share sales from the company, including one on August 31st for $1,608,143. ICU Medical specializes in medical products for infusion therapy, vascular access, and vital care.

Icu medical chief financial officer Brian Bonnell sells $1.1 million in stock

https://www.investing.com/news/insider-trading-news/icu-medical-chief-financial-officer-brian-bonnell-sells-11-million-in-stock-93CH-4886111
ICU Medical Inc.'s CFO, Brian Bonnell, sold 6,381 shares worth $1,116,675 on September 1, 2026, pursuant to a pre-arranged trading plan. Despite the sale, ICU Medical shares have risen 34% over the past year and are considered undervalued by InvestingPro, with analysts revising earnings upwards. The company also recently reported strong Q2 earnings, raised full-year guidance, and received a credit rating upgrade from S&P Global Ratings.

ICUI: ICU Medical, Inc. Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/ICUI
This article provides an overview of ICU Medical, Inc. (ICUI), including its current stock price ($161.60), market capitalization ($3.88B), and key financial metrics. It highlights the company's focus on innovative medical products for infusion therapy and critical care, and mentions recent news such as CFO stock sales and an analyst's market sentiment. The company was founded in 1984 and is headquartered in San Clemente, CA.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement